Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewBAY 6096 New
Description: Potent and selective adrenergic α2B antagonist
Chemical Name: 1-[2-[[[3-(3,5-Dimethyl-4-isoxazolyl)imidazo[1,2-a]pyridin-7-yl]carbonyl]amino]ethyl]-4-(methylamino)pyridinium chloride
Purity: ≥98% (HPLC)
Biological Activity for BAY 6096
BAY 6096 is a potent (IC50 = 14 nM), and selective adrenergic α2B receptor antagonist that displays 394, 725, >845-fold selectivity over α1A, α2A, and α2C, respectively. BAY 6096 reduces α2B receptor agonist-induced vasoconstriction and has a high clearance and low mean residence times in rats. BAY 6096 is highly water-soluble.
Licensing Information
This compound is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the BAY 6096 probe summary on the SGC website.
Technical Data for BAY 6096
| M. Wt | 426.91 |
| Formula | C21H23ClN6O2 |
| Storage | Store at -20°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 2313483-41-7 |
| PubChem ID | 153534231 |
| InChI Key | HVVLGXULBVAFRZ-UHFFFAOYSA-N |
| Smiles | O=C(C1=CC2=NC=C(C3=C(C)ON=C3C)N2C=C1)NCC[N+]4=CC=C(NC)C=C4.[Cl-] |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for BAY 6096
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| water | 42.69 | 100 | |
| DMSO | 42.69 | 100 |
Preparing Stock Solutions for BAY 6096
The following data is based on the product molecular weight 426.91. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.34 mL | 11.71 mL | 23.42 mL |
| 5 mM | 0.47 mL | 2.34 mL | 4.68 mL |
| 10 mM | 0.23 mL | 1.17 mL | 2.34 mL |
| 50 mM | 0.05 mL | 0.23 mL | 0.47 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for BAY 6096
References for BAY 6096
References are publications that support the biological activity of the product.
Meibom et al (2023) BAY-6096: A potent, selective, and highly water-soluble adrenergic a2B antagonist. J Med Chem 66 4659 PMID: 36932954
If you know of a relevant reference for BAY 6096, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: BAY 6096, BAY 6096 supplier, BAY6096, BAY-6096, Potent, selective, adrenergic, alpha2B, antagonists, in, vivo, α2B-adrenoceptor, adrenoceptors, α2b-adrenergic, alpha2b-adrenergic, a2b-adrenoceptor, receptors, Adrenergic, Alpha-2, Receptors, 8006, Tocris Bioscience
Citations for BAY 6096
Citations are publications that use Tocris products.
Currently there are no citations for BAY 6096. Do you know of a great paper that uses BAY 6096 from Tocris? Please let us know.
Reviews for BAY 6096
There are currently no reviews for this product. Be the first to review BAY 6096 and earn rewards!
Have you used BAY 6096?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.